Six new drugs are set to enter the market for ulcerative colitis (UC) within the next three years, just as some established therapies for the disease, including AbbVie Inc.’s Humira, begin to face generic competition.
A new report from Datamonitor Healthcare says the upcoming changes will lead to major pricing pressures in the field...